Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

PURPOSE: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (ARs) identified previously in flutamide-resistan...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Cancer Res
Main Authors: Chen, Eddy J., Sowalsky, Adam G., Gao, Shuai, Cai, Changmeng, Voznesensky, Olga, Schaefer, Rachel, Loda, Massimo, True, Lawrence D., Ye, Huihui, Troncoso, Patricia, Lis, Rosina L., Kantoff, Philip W., Montgomery, Robert B., Nelson, Peter S., Bubley, Glenn J., Balk, Steven P., Taplin, Mary-Ellen
格式: Artigo
語言:Inglês
出版: 2014
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359958/
https://ncbi.nlm.nih.gov/pubmed/25320358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1220
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍